IPSCS

Quell Therapeutics Appoints Tracey Lodie, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Biology, Life sciences, Induced stem cells, Biotechnology, T cells, Stem cells, Regulatory T cell, IPSCS, Induced pluripotent stem cell

LONDON and BOSTON, July 29, 2021 /PRNewswire/ --Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer.

Key Points: 
  • LONDON and BOSTON, July 29, 2021 /PRNewswire/ --Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer.
  • "We are delighted to welcome Tracey to Quell.
  • She brings impressive drug discovery experience working with a wide range of cell therapy platforms, including induced pluripotent stem cells (iPSCs), Treg and T-effector cells and genetic engineering," said Iain McGill, Chief Executive Officer of Quell Therapeutics.
  • "We believe that Tracey's extensive technical and therapeutic expertise enhances our industry leading engineered Treg cell therapy development capabilities and reinforces our proven operational competency.

Quell Therapeutics Appoints Tracey Lodie, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Biology, Life sciences, Induced stem cells, Biotechnology, Stem cells, T cells, IPSCS, Regulatory T cell, Induced pluripotent stem cell

LONDON and BOSTON, July 29, 2021 /PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer. Dr. Lodie brings to Quell more than 20 years of experience in the biopharmaceutical industry focused on the discovery and development of cell therapies and novel biologics in the areas of autoimmunity, transplant biology and immune-oncology.

Key Points: 
  • "We are delighted to welcome Tracey to Quell.
  • She brings impressive drug discovery experience working with a wide range of cell therapy platforms, including induced pluripotent stem cells (iPSCs), Treg and T-effector cells and genetic engineering," said Iain McGill, Chief Executive Officer of Quell Therapeutics.
  • "We believe that Tracey's extensive technical and therapeutic expertise enhances our industry leading engineered Treg cell therapy development capabilities and reinforces our proven operational competency.
  • Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases.

Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma

Retrieved on: 
Friday, July 16, 2021
Life sciences, Biology, Biotechnology, Induced stem cells, Developmental biology, Stem cells, IPSCS, Biopharmaceutical, Cellular differentiation, Induced pluripotent stem cell

The archived webcast will be available on the Company's website beginning approximately two hours after the event.

Key Points: 
  • The archived webcast will be available on the Company's website beginning approximately two hours after the event.
  • Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body.
  • Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.

Sana Biotechnology Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates

Retrieved on: 
Saturday, June 26, 2021
Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Cell biology, Developmental biology, Induced pluripotent stem cell, IPSCS, Immunosuppression

SEATTLE, June 26, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today presented data showing survival of transplanted stem cells without immunosuppression in non-human primates (NHPs).

Key Points: 
  • SEATTLE, June 26, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today presented data showing survival of transplanted stem cells without immunosuppression in non-human primates (NHPs).
  • The transplanted cells were induced pluripotent stem cells (iPSCs) with Sanas hypoimmune gene modifications that enable immune evasion.
  • Sanas hypoimmune (HIP) platforms goal is to eliminate the need for immunosuppression by cloaking cells from immune recognition.
  • Sana Biotechnology and the Sana Biotechnology logo are trademarks of Sana Biotechnology, Inc. or its subsidiaries.

Alphageneron to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th, 2021

Retrieved on: 
Saturday, June 26, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Cell biology, Induced stem cells, Immune system, Natural killer cell, Induced pluripotent stem cell, Cell therapy, IPSCS

CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (Alphageneronor theCompany), a privately-held clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer (NK) cellular and antibody therapeutics announced that Robert Brooks, JD, founder and Chief Executive Officer of Alphageneron, will participate in the ROTH Healthcare Private Company Forum to be hosted virtually on Monday, June 28, 2021.

Key Points: 
  • CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (Alphageneronor theCompany), a privately-held clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer (NK) cellular and antibody therapeutics announced that Robert Brooks, JD, founder and Chief Executive Officer of Alphageneron, will participate in the ROTH Healthcare Private Company Forum to be hosted virtually on Monday, June 28, 2021.
  • Alphageneron is also planning a Phase I clinical Combination trial with Metastatic Colorectal cancer withallogeneic donor genetically edited NK cell therapy, (ANKASTIM) in the United States.
  • To register for this virtual event click www.roth.com/healthcareprivateday or please contact Gerald Roger, c/o Trinity Capital Advisers Tel.
  • Alphageneron is also developing allogeneic Induced pluripotent stem cells (iPSCs) CAR-engineered NK (CAR NK) cells to an undisclosed target.

Global Induced Pluripotent Stem Cells Markets 2021-2026: Molecular and Cellular Engineering, Cellular Reprogramming, Cell Culture, Cell Differentiation, and Cell Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 24, 2021
Health, Stem cells, Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Developmental biology, Cell biology, Induced pluripotent stem cell, IPSCS, Cellular differentiation, Stem cell genomics

The "Global Induced Pluripotent Stem Cells Market: 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Induced Pluripotent Stem Cells Market: 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • Product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis.
  • For this report, iPSC products do not cover stem cell research and clinical products, which are broadly applicable to any stem cell type.
  • An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSCs market.

Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies

Retrieved on: 
Thursday, June 24, 2021
Branches of biology, Biology, Life sciences, Stem cells, Induced stem cells, Biotechnology, Developmental biology, Cell biology, Induced pluripotent stem cell, IPSCS, Cellular differentiation, Cell therapy

Upon completion, the acquisition will build upon Catalent's existing custom cell therapy process development and manufacturing capabilities with proprietary GMP cell lines for iPSC-based therapies.

Key Points: 
  • Upon completion, the acquisition will build upon Catalent's existing custom cell therapy process development and manufacturing capabilities with proprietary GMP cell lines for iPSC-based therapies.
  • iPSCs are cells that can be differentiated into various cell types to address a wide range of therapeutic indications.
  • "We formed RheinCell based on our deep scientific and regulatory expertise in the promising field of cell-based therapies," commented Juergen Weisser, Chief Executive Officer, RheinCell Therapeutics.
  • RheinCell develops and manufactures GMP-grade human induced pluripotent stem cells (iPSCs) for the next generation of cell therapies.

Olivier Gouédard, PharmD, MBA joins Cytovia Therapeutics as Chief Operating Officer

Retrieved on: 
Tuesday, June 22, 2021
Branches of biology, Life sciences, Biology, Immune system, Cancer immunotherapy, Stem cells, Lymphocytes, Biotechnology, Induced pluripotent stem cell, Chimeric antigen receptor T cell, Natural killer cell, IPSCS

and AVENTURA, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that Olivier Goudard, PharmD, MBA has been appointed as Chief Operating Officer, effective immediately.

Key Points: 
  • and AVENTURA, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that Olivier Goudard, PharmD, MBA has been appointed as Chief Operating Officer, effective immediately.
  • Dr. Goudard will lead cross-functional integration of external and internal R&D, manufacturing, regulatory affairs, and clinical development.
  • Were delighted to welcome Olivier to Cytovias leadership team, added Dr. Daniel Teper, CEO of Cytovia Therapeutics.
  • Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer.

I Peace's cell manufacturing facility "Peace Engine Kyoto" receives third-party certification as US cGMP compliant: the facility now meets the standard for both the US and Japanese markets

Retrieved on: 
Tuesday, May 25, 2021
IPSCS, Life sciences, Food and Drug Administration, Title 21 of the Code of Federal Regulations, Biology, Biotechnology, Stem cells

The facility was awarded a permit in 2020 by Japan's Ministry of Health, Labour, and Welfare to manufacture specific cell-based products.

Key Points: 
  • The facility was awarded a permit in 2020 by Japan's Ministry of Health, Labour, and Welfare to manufacture specific cell-based products.
  • The certification provides peace of mind to client organizations looking to use our iPSCs clinically and commercially in the US, Japan, and global markets for regulatory issues.
  • I Peace manufacturing facility (Peace Engine Kyoto) and its quality management system received a third-party certification as compliant with ICH-Q7, 21 CFR 210/211, and 21 CFR 1271.
  • However, when cell therapy developers seek regulatory approval for iPSC-derived cell therapies, the manufacturing process of iPSCs becomes subject to FDA review.

Cytovia Therapeutics CEO Dr. Daniel Teper to Present at Two Upcoming Conferences

Retrieved on: 
Friday, May 14, 2021
Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Lymphocytes, Immune system, IPSCS, Induced pluripotent stem cell, Natural killer cell, Cellectis

Cytovia focuses on Natural Killer (NK) cell biology and applies precision engineering to induced pluripotent stem cells (iPSCs) to develop the safest, most effective, most broadly-available off-the-shelf Natural Killer cell therapy as a first line of defense against cancer.

Key Points: 
  • Cytovia focuses on Natural Killer (NK) cell biology and applies precision engineering to induced pluripotent stem cells (iPSCs) to develop the safest, most effective, most broadly-available off-the-shelf Natural Killer cell therapy as a first line of defense against cancer.
  • Cytovia\xe2\x80\x99s proprietary multi-specific antibody platform has been customized to engage and activate NK Cells at the tumor site.
  • Both platforms offer optionality to clinicians and can also be used synergistically.
  • Cytovia\xe2\x80\x99s R&D laboratories and GMP manufacturing facility are augmented by scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, STC Biologics, and the University of California San Francisco (UCSF).\n'